Thu, May 15, 12:40 PM (39 days ago)
**GRI Bio, Inc. (GRI: Nasdaq Capital Market) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No significant revenue reported, consistent with prior quarters. - **Profit Margins:** Negative, with a net loss of $3,046,000 for Q1 2025, compared to $1,887,000 in Q1 2024. - **Cash Flow:** Negative cash flow from operations at $1,736,000 for Q1 2025, down from $2,203,000 in Q1 2024. - **Earnings Changes:** Net loss per share increased to $5.80 in Q1 2025 from $101.05 in Q1 2024, due to reverse stock splits. **Operational Performance:** - **Expenses:** Total operating expenses rose to $3,051,000 in Q1 2025 from $1,895,000 in Q1 2024, driven by increased research and development (R&D) and general and administrative (G&A) costs. - **R&D:** Increased to $1,640,000 in Q1 2025 from $933,000 in Q1 2024, focusing on GRI-0621 and GRI-0803. - **G&A:** Increased to $1,411,000 in Q1 2025 from $962,000 in Q1 2024, due to higher personnel and professional fees. **Trends and Uncertainties:** - **Funding:** Raised $5,000,000 in April 2025 through a securities purchase agreement and $3,467,000 from an ATM offering by March 31, 2025. - **Liquidity:** Cash position of $3,281,000 as of March 31, 2025, sufficient to fund operations through Q3 2025. - **Going Concern:** Substantial doubt about continuing as a going concern due to reliance on additional financing. **Future Operations Impact:** - **Clinical Trials:** Phase 2a biomarker study for GRI-0621 expected to yield interim data in Q2 2025 and topline results in Q3 2025. - **Product Development:** GRI-0803 development on hold pending additional funding and IND clearance. - **Financial Strategy:** Plans to raise capital through equity issuances and debt arrangements to support ongoing operations and clinical trials. **Summary:** GRI Bio, Inc. continues to operate at a loss, with increasing expenses driven by R&D and G&A costs. The company relies on external financing to sustain operations and advance its clinical programs. The upcoming data from the GRI-0621 trial and potential funding rounds will be critical for the company's future prospects.